Effect of spironolactone on patients with atrial fibrillation and structural heart disease

Clinical Cardiology

Volumn 34, Issue 7, 2011, Pages 415-419

  Williams, Ryan S ^b   Delemos, James A ^b   Dimas, Vassilis ^b   Reisch, Joan ^b   Hill, Joseph A ^b,c   Naseem, R Haris ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; ELECTRIC COUNTERSHOCK; FEMALE; FIBROSIS; HEART DISEASES; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPIRONOLACTONE; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960437223     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20914     Document Type: Article

References (21)

1. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990; 322: 863-868.
2. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001; 37: 371-378.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114: 119-125. (Pubitemid 44420743)
4. Wolf PA, Abbott RD, Kannel WB., Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987; 147: 1561-1564. (Pubitemid 17138836)
5. Wolf PA, Abbott RD, Kannel WB., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-988.
6. Cairns JA, Connolly SJ., Nonrheumatic atrial fibrillation: risk of stroke and role of antithrombotic therapy. Circulation. 1991; 84: 469-481.
7. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98: 946-952. (Pubitemid 28446646)
8. Nattel S, Burstein B, Dobrev D., Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008; 1: 62-73.
9. Ehrlich JR, Nattel S., Novel approaches for pharmacological management of atrial fibrillation. Drugs. 2009; 69: 757-774.
10. Spach MS, Boineau JP., Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. Pacing Clin Electrophysiol. 1997; 20: 397-413.
11. Miragoli M, Gaudesius G, Rohr S., Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res. 2006; 98: 801-810.
12. Miragoli M, Salvarani N, Rohr S., Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res. 2007; 101: 755-758. (Pubitemid 350287189)
13. Massare J, Berry JM, Luo X, et al. Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype. J Cardiovasc Electrophysiol. 2010; 21: 1030-1037.
14. Burstein B, Nattel S., Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008; 51: 802-809. (Pubitemid 351260071)
15. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007; 74: 75-84. (Pubitemid 46366949)
16. Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol. 2009; 53: 24-29.
17. Tsai CT, Chiang FT, Tseng CD, et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol. 2010; 55: 758-770.
18. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002; 54: 361-379. (Pubitemid 34327915)
19. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180-1184. (Pubitemid 27344221)
20. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004; 109: 363-368. (Pubitemid 38133905)
21. Zhao J, Li J, Li Y, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol. 2010; 159: 1584-1594.